{"product_id":"biolegend-329901","title":"Biolegend, 329901, Purified anti-human CD279 (PD-1) Antibody, 25μg","description":"\u003cp\u003eProgrammed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.\u003cbr\u003e\n25μg\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography.\u003cbr\u003e\nConcentration: 0.5 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C.\u003cbr\u003e\nApplication: FC - Quality tested Block, IHC-F - Reported in the literature, not verified in house\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nApplication Notes: Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin \u0026lt;0.01 EU\/µg).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA) Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA) Velu V, et al. 2007. J. Virol. 81:5819. (FA) Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA) Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity) Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC) Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG) Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Dhariwala MO, et al. 2020. Cell Rep Med. 1:100132. PubMed Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed Alpert A, et al. 2022. Cell Syst. 13:71. PubMed Leader AM, et al. 2021. Cancer Cell. 39:1594. PubMed McCarthy EE, et al. 2022. Cell Rep. 39:110815. PubMed Gernoux G, et al. 2020. Mol Ther. 28:747. PubMed Yonemitsu K, et al. 2022. Sci Rep. 12:12007. PubMed Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed Lu X, et al. 2018. Am J Cancer Res. 8:1564. PubMed Chakhtoura M, et al. 2021. PLoS Pathog. 17:e1009732. PubMed Mann ER, et al. 2020. Sci Immunol. :5. PubMed Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed Dean JW, et al. 2020. J Autoimmun. 108:102417. PubMed Kondo H, et al. 2022. Front Immunol. 13:836923. PubMed Hsu DC, et al. 2018. Clin Infect Dis. 67:437. PubMed Liu F, et al. 2020. J Immunother Cancer. 8:. PubMed O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed Cobb DA, et al. 2022. J Immunother Cancer. 10:. PubMed Mirzaei R, et al. 2021. Sci Adv. 7:eabh2148. PubMed Del Alcazar D, et al. 2019. Cell Rep. 28:3047. PubMed Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed Gee MH, et al. 2018. Cell. 172:549. PubMed Conrad J, et al. 2012. J Virol. 86:4213. PubMed Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed Macmillan ML, et al. 2021. Blood Adv. 5:1425. PubMed Zahn R, et al. 2008. J Virol. 82:11577. PubMed Schwabenland M, et al. 2021. Immunity. . PubMed Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed Stervbo U, et al. 2019. Front Immunol. 0.949305556. PubMed Anna F, et al. 2021. J Immunother Cancer. 9:. PubMed Saber MM, et al. 2022. Antibodies (Basel). 11:. PubMed Kim MH, et al. 2018. Cancer Immunol Res. 0.427083333. PubMed Conrad J, et al. 2011. J Immunol. 186:6871. PubMed Monteiro P, et al. 2011. J Immunol. 186:4618. PubMed Stensland ZC, et al. 2022. iScience. 25:103626. PubMed Kim A, et al. 2019. J Immunol. 203:1076. PubMed Lewinsky H, et al. 2018. J Clin Invest. 128:5465. PubMed Vojnov L, et al. 2010. J Virol. 84:753. PubMed Tang X, et al. 2020. Sci Adv. 6:eaaz0374. PubMed Nicholas K, et al. 2015. Cytometry A. 10.1002\/cyto.a.22799. PubMed Enyindah-Asonye G, et al. 2019. Front Immunol. 10:511. PubMed Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed Hwang HJ, et al. 2021. Immun Inflamm Dis. 9:274. PubMed Chiou SH, et al. 2021. Immunity. 54:586. PubMed\u003cbr\u003e\nRRID: AB_940488 (BioLegend Cat. No. 329902)\u003cbr\u003e\nStructure: Immunoglobulin superfamily\u003cbr\u003e\nDistribution: Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells\u003cbr\u003e\nLigand\/Receptor: B7-H1 (also known as PD-L1) and B7-DC (PD-L2)\u003cbr\u003e\nCell Type: B cells, Lymphocytes, T cells, Thymocytes, Tregs\u003cbr\u003e\nBiology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules\u003cbr\u003e\nMolecular Family: CD Molecules, Immune Checkpoint Receptors\u003cbr\u003e\nGene ID: 5133\u003cbr\u003e\nUniProt: View information about CD279 on UniProt.org\u003cbr\u003e\nClone: EH12.2H7\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: PD-1, PDCD1\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46863073607849,"sku":"329901","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-329901","provider":"Iright","version":"1.0","type":"link"}